Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiomegaly Clear all
Terminated Not applicable Interventional Results available

Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease

NCT04176458
View directory record Official record
Conditions
Dilated Cardiomyopathy, Tricuspid Atresia
Interventions
Methacetin Breath Test (MBT)
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Not applicable Interventional

Optimizing Left Ventricular Lead To Improve Cardiac Output

NCT01399801
View directory record Official record
Conditions
Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy, Congestive Heart Failure
Interventions
Doppler flow measurement, standard implantation of the LV lead
Procedure
Lead sponsor
Ann Marie Chikowski
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Not applicable Interventional

Point-of-care Ultrasound and Treatment Disparities for Left Ventricular Hypertrophy

NCT05730309
View directory record Official record
Conditions
Left Ventricular Hypertrophy
Interventions
Customized discharge and expedited referral instructions
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 10, 2026, 7:39 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

NCT07137338
View directory record Official record
Conditions
Dilated Cardiomyopathy (DCM)
Interventions
RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)
Genetic
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
San Diego, California • Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 10, 2026, 7:39 PM EDT
Active, not recruiting Not applicable Interventional

DCM Precision Medicine Study

NCT03037632
View directory record Official record
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Family Heart Talk Booklet
Behavioral
Lead sponsor
Ray Hershberger
Other
Eligibility
Not listed
Enrollment
6,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

NCT03180593
View directory record Official record
Conditions
Hypertension Complicated, Hypertrophy, Left Ventricular, Blood Pressure
Interventions
Valsartan 80 mg
Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 10, 2026, 7:39 PM EDT
Terminated Phase 3 Interventional Results available

Hypertension in Hemodialysis Patients (Aim 3)

NCT00582114
View directory record Official record
Conditions
Hemodialysis, Hypertension, Left Ventricular Hypertrophy
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

NCT03447990
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
Interventions
MYK-491, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Jacksonville, Florida • Saint Paul, Minnesota • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 10, 2026, 7:39 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study

NCT04638621
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 10, 2026, 7:39 PM EDT
Recruiting Phase 2 Interventional

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

NCT06092034
View directory record Official record
Conditions
Danon Disease
Interventions
RP-A501
Genetic
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
3
States / cities
La Jolla, California • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Phase 4 Interventional

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

NCT00139555
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
amlodipine/benazepril
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 10, 2026, 7:39 PM EDT
Completed No phase listed Observational

Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease

NCT00027196
View directory record Official record
Conditions
Congenital Heart Defect
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
9,999,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 10, 2026, 7:39 PM EDT
Recruiting Phase 2 Interventional

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

NCT07721025
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions
LX2006, Usual Care
Genetic · Other
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Phase 3 Interventional Results available

The CLEVER Study - Coreg And Left Ventricular Mass Regression

NCT00108082
View directory record Official record
Conditions
Hypertrophy, Left Ventricular
Interventions
carvedilol MR, atenolol, lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 10, 2026, 7:39 PM EDT
Terminated No phase listed Observational

Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

NCT01427374
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

NCT01392625
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
Autologous hMSCs, Allogeneic hMSCs
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 10, 2026, 7:39 PM EDT
Terminated No phase listed Observational

NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy

NCT00293137
View directory record Official record
Conditions
Chronic Systolic Heart Failure (Dilated Cardiomyopathy)
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available

A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

NCT02351856
View directory record Official record
Conditions
LMNA-Related Dilated Cardiomyopathy
Interventions
ARRY-371797, p38 inhibitor, oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 10, 2026, 7:39 PM EDT
Not listed No phase listed Observational

Electrophysiologic and Morphologic Assessment of the Substrate to Guide Implantation of Defibrillators in Dilated Cardiomyopathy

NCT01378572
View directory record Official record
Conditions
Dilated Cardiomyopathy, Primary Prevention of Sudden Cardiac Death, Implantable Cardioverter Defibrillator
Interventions
Not listed
Lead sponsor
Catholic University of the Sacred Heart
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818
View directory record Official record
Conditions
Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Genetic · Procedure
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
22
States / cities
San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 10, 2026, 7:39 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Imaging Histone Deacetylase in the Heart

NCT03549559
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, Aortic Valve Stenosis, Diabetes
Interventions
11C-Martinostat, PET-MRI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 10, 2026, 7:39 PM EDT
Completed Phase 2 Interventional

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

NCT00765518
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
Ixmyelocel-T, Standard of Care
Biological · Other
Lead sponsor
Vericel Corporation
Industry
Eligibility
18 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Cleveland, Ohio • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 10, 2026, 7:39 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 10, 2026, 7:39 PM EDT
Recruiting Not applicable Interventional

Sodium Lowering Vascular Effects Trial

NCT05388032
View directory record Official record
Conditions
Endothelial Dysfunction, Vascular Stiffness, Left Ventricular Hypertrophy, Left Ventricular Dysfunction
Interventions
Sodium Reduction Intervention
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 10, 2026, 7:39 PM EDT